SITC Workshop on New Perspectives for Target Antigens in the Changing Cancer Immunotherapy Landscape

The SITC 2015 Presentation Archive is supported through a generous contribution from AstraZeneca/MedImmune.

Access slide decks and video via the links in the schedule below.

= PDF of slides is available

= Presentation video is available

Program Schedule

Thursday, November 5, 2015
 

8 – 8:05 a.m.	Opening Remarks Paul F. Robbins, PhD – National Cancer Institute/National Institutes of Health
Session I: Approaches used to Identify Tumor Antigens 2 AMA PRA Category 1 Credits™
8:05 – 8:35 a.m.	Use of Whole Exome and RNAseq Analysis to Identify Mutated Tumor Neo-Antigens     Elaine Mardis, PhD – The Genome Institute at Washington University School of Medicine
8:35 – 9:05 a.m.	Proteomics Strategies that Facilitate Tumor Antigen Identification Victor H. Engelhard, PhD – University of Virginia School of Medicine
9:05 – 9:35 a.m.	Immune-regulation at the Tumor Site: Defining the Immune and Neoantigenic Landscape in Lung Cancer Sergio Quezada, PhD – University College London Cancer Institute
9:35 – 10 a.m.	Panel Discussion
10 – 10:30 a.m.	Break
Session II: Characterization and Isolation of Specific T cells for Therapy 2 AMA PRA Category 1 Credits™
10:30 – 10:35 a.m.	Session II Introduction
10:35 – 11:05 a.m.	Use of MHC Multimers to Identify Tumor Reactive T Cells   John Haanen, PhD – Netherlands Cancer Institute
11:05 – 11:35 p.m.	Identification of Antigens Targeted by Tumor Infiltrating Lymphocytes to Enhance Adoptive Immunotherapy   Eric Tran, PhD – National Institutes of Health/National Institute of Health- Surgery Branch
11:35 – 12:05 p.m.	Evaluation of Strategies for T Cell Gene Engineering Laurence J.N. Cooper, MD, PhD – University of Texas MD Anderson Cancer Center
12:05 – 12:30 p.m.	Panel Discussion
12:30 – 1:30 p.m.	Lunch
Session III: Antigen Discovery: Enabling the Next Generation of Immunotherapies 2.5 AMA PRA Category 1 Credits™
1:30 – 1:35 p.m.	Session III Introduction
1:35 – 2:05 p.m.	Targeting the Mutanome for Individualized Cancer Immunotherapy   Ugur Sahin, MD – University Medical Center of the Johannes Gutenberg University Mainz
2:05 – 2:35 p.m.	Antigens Targeted by Checkpoint Blockade     Alexandra Snyder Charen, MD – Memorial Sloan Kettering Cancer Center
2:35 – 3:05 p.m.	Control of Tumor Immunity in Humans   Catherine Wu, MD – Dana-Farber Cancer Institute
3:05 – 3:30 p.m.	Panel Discussion
3:30 – 4 p.m.	Final Overview